

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following results were reported with the combination of pembrolizumab and axitinib in the Phase III KEYNOTE-426 trial, which evaluated the efficacy and safety of that combination versus sunitinib monotherapy as first-line therapy for patients with advanced renal cell carcinoma (RCC)?**
 - A statistically significant improvement in objective response rate (ORR) and progression-free survival (PFS) but not overall survival (OS)
 - A statistically significant improvement in ORR and OS but not PFS
 - A statistically significant improvement in ORR, PFS and OS**
- 2. First results from the Phase III CheckMate 9ER trial included which of the following outcomes with the combination of nivolumab/cabozantinib versus sunitinib as first-line therapy for advanced RCC?**
 - A statistically significant improvement in PFS but not OS
 - A statistically significant improvement in OS but not PFS
 - A statistically significant improvement in PFS and OS**
- 3. On the Phase III CheckMate 214 trial, which evaluated nivolumab with ipilimumab versus sunitinib monotherapy as first-line therapy for advanced RCC, in which patient subgroup was the benefit with the combination greater?**
 - Patients with favorable-risk disease
 - Patients with intermediate- or poor-risk disease**
- 4. Which of the following combinations is being compared to sunitinib as first-line therapy for patients with advanced RCC in the Phase III CLEAR trial?**
 - Lenvatinib with everolimus or pembrolizumab**
 - Lenvatinib with nivolumab or pembrolizumab
 - Cabozantinib with everolimus or pembrolizumab
 - Pazopanib with nivolumab or pembrolizumab